Whether oral hydroxyurea (fixed-dose, dose-escalation, and maximum tolerated dose [MTD] phases) increases clinically diagnosed infection rates in children aged 1–10 years with sickle cell anaemia across four sub-Saharan African countries (Angola, DR Congo, Kenya, Uganda) in the REACH trial (2014–2016).
Hydroxyurea did not increase infection risk; non-malarial infection rates fell significantly from screening to MTD phase (adjusted IRR 0.51, 95% CI 0.43–0.61, p<0.0001). Across 5,638 person-years, 5,493 infections occurred (97.4/100 PYO overall), with decreases seen in upper and lower respiratory tract infections, bacterial skin/nail infections, non-specific infectious syndromes, and grade ≥3 infections at MTD.
Open-label, single-arm design with no concurrent control group means confounding over time cannot be fully excluded. Infections were clinically diagnosed without systematic laboratory confirmation, limiting aetiological certainty. The cohort was drawn from four specific African hospital settings, which may limit generalisability to other regions or healthcare contexts.
Clinicians can reassure families that hydroxyurea—even at maximum tolerated dose—does not raise the risk of serious infections in children with sickle cell anaemia; infection rates actually declined as treatment progressed.